Friday - February 20, 2026

Category Archives: Marketing & Sales

Metastatic Prostate Cancer Clinical Trial Pipeline Advances as 80+ Companies Develop 85+ Pipeline Drugs Across Multiple Stages, Finds DelveInsight | Merck, AstraZeneca, Syntrix Pharmaceuticals

Metastatic Prostate Cancer – Pipeline Insight, 2026 DelveInsight’s “Metastatic Prostate Cancer – Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies including AstraZeneca, Arvinas, Daiichi Sankyo, Bristol Myers Squibb, Merck, MacroGenics, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, … Continue reading →

Uveitis Clinical Trial Pipeline Expands as 15+ Companies Advance 15+ Targeted Ocular Inflammation Therapies Toward Market Entry, Finds DelveInsight | Santen, Clearside Biomedical, Tarsier Pharma

Uveitis – Pipeline Insight, 2026 DelveInsight’s “Uveitis – Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, … Continue reading →

Degenerative Disc Disease Clinical Trial Pipeline Strengthens as 15+ Companies Advance 15+ Regenerative and Non‑Surgical Therapies Toward Market Entry, Finds DelveInsight | Spine BioPharma, Biosplice

“Degenerative Disc Disease – Pipeline Insight, 2026 DelveInsight’s “Degenerative Disc Disease – Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies, including include Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes Inc., DiscGenics, Kuros Biosciences, … Continue reading →

Celiac Disease Clinical Trial Pipeline Gains Momentum as 25+ Companies Advance Novel Therapies Toward Market Entry: DelveInsight | Teva Pharmaceutical Industries, Barinthus Biotherapeutics, Topas

Celiac Disease – Pipeline Insight, 2026 DelveInsight’s “Celiac Disease – Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies, including Teva Pharmaceutical Industries Ltd., Sanofi, Forte Biosciences, Inc., Takeda, Anokion, Entero Therapeutics, Amgen, Topas Therapeutics, Mozart Therapeutics Australia Pty … Continue reading →

Bronchiectasis Clinical Trial Pipeline Expands as 15+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Insmed, Boehringer Ingelheim, CSL, RedHill, Chies

Bronchiectasis – Pipeline Insight, 2026 DelveInsight’s “Bronchiectasis – Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies, including AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion … Continue reading →

Thymidine Kinase 2 Deficiency Market to Grow Rapidly by 2034, DelveInsight Observes | UCB Biosciences

Thymidine Kinase 2 Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 The Thymidine Kinase 2 Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thymidine Kinase … Continue reading →

Friedreich’s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx

Friedreich’s Ataxia – Pipeline Insight, 2026 DelveInsight’s “Friedreich’s Ataxia – Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies including PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics and others, … Continue reading →

IgA Nephropathy (IgAN) market across the 7MM is estimated at approximately USD 878 million in 2025, analyses DelveInsight

IgA Nephropathy market Leading companies such as Vertex Pharmaceuticals, Vera Therapeutics, Novartis, and AstraZeneca (Alexion Pharmaceuticals) are actively advancing new treatment options. The IgA Nephropathy (IgAN) market across the seven major markets (7MM) is estimated at approximately USD 878 million … Continue reading →

Platinum-Resistant Ovarian Cancer Market to Surge by 2034 Across 7MM | 5+ Emerging Therapies and 60K+ Annual Cases Driving Innovation, Reports DelveInsight

Platinum-Resistant Ovarian Cancer Market The platinum-resistant ovarian cancer market is witnessing notable growth, fueled by significant unmet medical needs, as a substantial proportion of patients relapse following first-line platinum-based chemotherapy, thereby intensifying the demand for innovative second- and later-line therapeutic … Continue reading →